Russia plans to launch production of domestic medicines for hepatitis C

Russia plans to launch the production of domestic hepatitis C drugs if the Federal Antimonopoly Service (FAS) grants compulsory licenses to Russian manufacturers. This was told to Izvestia in the department.

Tread marks: there is a shortage of an unparalleled drug for cancer patients in the Russian Federation

How long will the mesna reserves last and when will the country have its own production?

"The reference medicines Epclusa and Maviret are currently protected by patents. Therefore, Russian manufacturers of generics cannot put them into circulation. To do this, they must obtain a voluntary production license from a foreign company or a compulsory one when the government gives permission for this. If such licenses are obtained, pharmaceutical companies guarantee their sale at even lower prices than those agreed by the service," the FAS explained.

They also noted that the service is working on such a measure for Russian generics as issuing a compulsory license, that is, obtaining government permission for their production and launch into circulation.

"This will reduce the cost of treating the disease, as well as increase the availability and expand the choice of such drugs for citizens. They will have to be provided free of charge in medical organizations as part of the state guarantees program for free medical care," the FAS stressed.

Read more in the exclusive Izvestia article:

They will take into account: in the Russian Federation, the cost of treatment for hepatitis C may be reduced